Life Cycle Leader for Pegozafermin (MASH)
Genentech | |
relocation assistance
| |
United States, California, South San Francisco | |
Nov 07, 2025 | |
|
The Position
Who we are At Roche, we are passionate about transforming patients' lives, and we are bold in both decision and action - we believe that good business means a better world. That is why we come to work every single day. We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow. Roche is strongly committed to a diverse and inclusive workplace. We strive to build teams that represent a range of backgrounds, perspectives, and skills. Embracing diversity enables us to create a great place to work and to innovate for patients. The Opportunity Our Global Pharma Strategy (GPS) team plays a pivotal role in shaping the future of healthcare by driving the strategic direction of our innovative product portfolio. As a member of the GPS team, you will be at the forefront of transforming groundbreaking scientific discoveries into accessible and impactful healthcare solutions for patients worldwide. We are seeking a dynamic and visionary professional who thrives in a collaborative environment and is passionate about making a difference. About The Position You will be responsible for our Pegozafermin asset, currently in Phase 3 for the treatment of MASH. Pegozafermin (FGF-21 analog) is our latest portfolio addition following the acquisition of 89Bio. Data readouts are expected from 2027, with the first filing expected soon after. Pegozafermin could be among the first launches in CVRM for Roche and represents a treatment option addressing significant unmet needs in a population with very limited current treatment options. The CVRM Team Cardiovascular, Renal, and Metabolism (CVRM) is a new and important therapy area at Roche. We are building a broad and deep pipeline of assets with the potential to significantly impact people living with chronic diseases across obesity, diabetes (Type 1 and Type 2), MASH, and cardiovascular diseases (HTN, ASCVD, etc.). As a team, we hold overall accountability for late-stage assets by leading and connecting the organization via asset-specific life cycle teams. We also provide strategic insights and guidance to research and early development for internal and external innovation in the CVRM space. We pride ourselves on understanding the external ecosystem and competitive environment to develop impactful strategies that will advance standards of care and become best-in-disease/class medicines upon launch. We aim to challenge the status quo, empower patients to achieve their full potential in life, and know that every step counts. Key Responsibilities
Who You Are
Preferred Candidate Profile
What success looks like in the role:
Join us in our mission to advance science and deliver hope to those who need it most. Location The primary location is South San Francisco with additional locations being Boston and Basel, Switzerland. Relocation assistance is available for this position. Compensation The expected salary range for this position based on the primary location of South San Francisco, is $346,800/yr to $455,175/yr. Actual pay will be determined based on experience, qualifications, and other job-related factors permitted by law. A discretionary annual bonus may be available based on individual and Company performance. This position also qualifies for the benefits detailed at the link provided below. [LINK] Genentech is an equal opportunity employer. It is our policy and practice to employ, promote, and otherwise treat any and all employees and applicants on the basis of merit, qualifications, and competence. The company's policy prohibits unlawful discrimination, including but not limited to, discrimination on the basis of Protected Veteran status, individuals with disabilities status, and consistent with all federal, state, or local laws. If you have a disability and need an accommodation in relation to the online application process, please contact us by completing this form Accommodations for Applicants. | |
relocation assistance
Nov 07, 2025